PMC:7306567 / 17450-17641
Annnotations
LitCovid-PD-FMA-UBERON
| Id | Subject | Object | Predicate | Lexical cue | fma_id |
|---|---|---|---|---|---|
| T21 | 45-51 | Body_part | denotes | plasma | http://purl.org/sig/ont/fma/fma62970 |
LitCovid-PubTator
| Id | Subject | Object | Predicate | Lexical cue | tao:has_database_id |
|---|---|---|---|---|---|
| 193 | 4-17 | Chemical | denotes | isavuconazole | MESH:C508735 |
LitCovid-PD-CLO
| Id | Subject | Object | Predicate | Lexical cue |
|---|---|---|---|---|
| T113 | 45-51 | http://purl.obolibrary.org/obo/UBERON_0001969 | denotes | plasma |
| T114 | 137-138 | http://purl.obolibrary.org/obo/CLO_0001020 | denotes | a |
LitCovid-PD-CHEBI
| Id | Subject | Object | Predicate | Lexical cue | chebi_id |
|---|---|---|---|---|---|
| T120 | 4-17 | Chemical | denotes | isavuconazole | http://purl.obolibrary.org/obo/CHEBI_85979 |
LitCovid-sentences
| Id | Subject | Object | Predicate | Lexical cue |
|---|---|---|---|---|
| T116 | 0-191 | Sentence | denotes | For isavuconazole, there is no robust target plasma concentration, and the population average exposure of participants that demonstrated a favorable response (2–4 mg/L) is commonly used [43]. |
LitCovid-PMC-OGER-BB
| Id | Subject | Object | Predicate | Lexical cue |
|---|---|---|---|---|
| T139 | 4-17 | CHEBI:85979;CHEBI:85979 | denotes | isavuconazole |
| T140 | 45-51 | UBERON:0001969 | denotes | plasma |
| T73675 | 4-17 | CHEBI:85979;CHEBI:85979 | denotes | isavuconazole |
| T42840 | 45-51 | UBERON:0001969 | denotes | plasma |
2_test
| Id | Subject | Object | Predicate | Lexical cue |
|---|---|---|---|---|
| 32572532-29544767-47963441 | 187-189 | 29544767 | denotes | 43 |
| T51946 | 187-189 | 29544767 | denotes | 43 |